EcoDrugPlus

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSORLG00000003592
Gene Symbol: HTR7
4 Cross references
196 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSORLG00000008245
Gene Symbol: LOC101170879
4 Cross references
317 Possible Orthologues:

60s Ribosomal Protein L22

Ensembl ID : ENSORLG00000019399
Gene Symbol: LOC101175136
3 Cross references
208 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSORLG00000016733
Gene Symbol: ARAF
4 Cross references
191 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSORLG00000007426
Gene Symbol: ABL1
4 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSORLG00000018108
Gene Symbol: ADAM17
4 Cross references
210 Possible Orthologues:

Adam Metallopeptidase Domain 17a

Ensembl ID : ENSORLG00000015321
Gene Symbol: ADAM17A
4 Cross references
208 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSORLG00000004966
Gene Symbol: ADAMTS5
4 Cross references
199 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSORLG00000017024
Gene Symbol: AKT1
4 Cross references
195 Possible Orthologues:

Apex Nuclease (Multifunctional Dna Repair Enzyme) 1

Ensembl ID : ENSORLG00000012378
Gene Symbol: APEX1
4 Cross references
212 Possible Orthologues:

Aph1b Gamma Secretase Subunit

Ensembl ID : ENSORLG00000018404
Gene Symbol: APH1B
4 Cross references
190 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSORLG00000017141
Gene Symbol: ABCC1
4 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).